NL-OMON43199已完成不适用
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation: AfterDmab - After Dmab
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Postmenopausal women with osteoporosis (T-score <-2.5) who reached a T score of >-2.5 on the LS spine and/or Fn Neck while on treatment with denosumab attending the outpatient clinic and willing to participate.
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:;i) secondary osteoporosis; ii) diseases that could affect bone metabolism other then osteoporosis; iii) medications that could affect bone metabolism; iv) history of any antiosteoporotic treatment other than denosumab prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
Study to investigate changes in BMD of the lumbar spine (LS) one year after treatment discontinuation in denosumab-treated women and in denosumab-treated women who received a single infusion of zoledronic acid after treatment discontinuation.EUCTR2016-000852-91-NLeiden University Medical Center75
进行中（未招募）
1 期
Zoledronic acid for prevention of bone loss after bariatric surgeryMorbid obese subjects undergoing bariatric surgeryEUCTR2019-001650-26-DKHospital South West Jutland70
尚未招募
4 期
Zoledronic acid to improve low bone mineral density in non-ambulatory adults with cerebral palsycerebral palsyMusculoskeletal - OsteoporosisNeurological - Other neurological disordersosteoporosisACTRN12615001048572Anne Trinh40
已完成
3 期
Zoledronic Acid in Acute Spinal Cord InjurySpinal Cord InjuryNCT01642901Thomas Jefferson University16
已完成
2 期
Zoledronic Acid for Prevention of Bone Loss After BAriatric Surgery (ZABAS)Bone LossMuscle AtrophyBariatric SurgeryNCT04742010Stinus Gadegaard Hansen59